| HOME >> BIOLOGY >> TECHNOLOGY |
NEW YORK, April 17 /PRNewswire-FirstCall/ -- SPO Medical Inc. (OTC: SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced that it has retained the services of American Capital Ventures (ACV), a leading provider of comprehensive investor relations services to the small cap community, as an investor relations consultant.
Michael Braunold, President and Chief Executive Officer of SPO Medical commented, "As we continue to grow our revenues and enhance our distribution base, it has become increasingly important to reach out to the investment community. Our goal is to inform current and prospective investors of our financial prospects and the value proposition offered by our product pipeline and strategy." Mr. Braunold continued, "Our portable devices and new consumer applications will appeal to an ever growing number of markets globally. This is a powerful message we need to convey to investors and American Capital Ventures has a proven track record assisting small cap companies in communicating their message to the investor community."
Howard Gostfrand, President of American Capital Ventures, commented, "SPO Medical has positioned itself well in the burgeoning medical field of non-invasive devices. They have clearly laid the groundwork with key investments and strategic partnerships that have been delivering tangible results. Achieving revenues of $5 million in 2007 after only three years, and with an impressive product channel, SPOM is a perfect example of a promising undiscovered small cap company worth an investor's consideration."
About SPO Medical
SPO Medical (SPOM) is a leading developer of biosensor and
microprocessor technologies for use in portable monitoring devices to
capture life-saving and life-enhancing information within four key markets:
medical care; home and remote-care; sports and wellness; and safety and
security. Its patented technology uses
'/>"/>
| SOURCE SPO Medical Inc Copyright©2008 PR Newswire. All rights reserved |